Stock Ratings / Health Care / MLSS / dividends

HSCS (39) LFWD (31) COCH (35) MYO (33) ⌘ Pro Terminal →

Milestone Scientific Inc. (MLSS) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.30 -3.30% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.30

Milestone Scientific Inc. (MLSS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $28.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MLSS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MLSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Milestone Scientific Inc. (NYSE: MLSS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.30 (-3.30% 1D, market cap $28.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, MLSS ranks #536 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MLSS compare to HSCS and LFWD in the Health Care sector?

▼

Within the Health Care sector (Industrial Specialties), MLSS carries a Roarable D- (40/100 RQD), trailing P/E of 5.0x, gross margin of 71.4%, and ROIC of -35.0%. By comparison, HSCS (HeartSciences Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $17.5M) and LFWD (Lifeward Ltd.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while MLSS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MLSS?

▼

Per MLSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000855683), Milestone Scientific Inc. generated $9.0M in revenue (+4.0% YoY), $5.7M in net income, and -$2.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.30 (-0.78%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MLSS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY MLSS SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)

Macro rate sensitivity & RSI-14 (40.8) create a -16 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.35-5.7% Next Q

Q2 (-2Q)

Grade D$0.33-9.1% Next Q

Q3 (-1Q)

Grade D$0.30+0% Next Q

Current

Grade D-$0.30-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MLSS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MLSS currently carries a cautious 40/100 (D-) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.39) and Max Pain ($0.32) forces dealer call-delta covering toward $0.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MLSS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MLSS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MLSS)

✓Walkthrough of MLSS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MLSS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.29%🛡️ HOLDING TREND SUPPORT

2026-11-02O $0.32H $0.32L $0.30C $0.30VOL 263.5K

RES: $0.66SUP: $0.28SMA50: $0.39SMA200: $0.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MLSS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MLSS Butterfly Map → + Track MLSS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-14.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MLSS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MLSS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MLSS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MLSS)

Health Care Rank #536 of 1016 ⚔️ HSCS vs MLSS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MLSS vs. HSCS, LFWD, COCH, MYO)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Milestone Scientific Inc. (MLSS) ranks #536 by composite RQD confidence (40/100, grade D-) and #809 by equity capitalization ($28.6M). Within this direct 5-issuer industry benchmark cohort, MLSS leads on earnings valuation at 5.0x trailing P/E, while MLSS leads on capital efficiency and profitability with -35.0% ROIC and 71.4% gross margin. MLSS currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MLSS ACTIVE Milestone Scientific Inc.	D-	40/100	5.0x	71.4%	-35.0%	-3.30%	$28.6M	Benchmark Subject
HSCS HeartSciences Inc.	D-	39/100	—	59.1%	-35.0%	-8.31%	$17.5M	/hscs-vs-mlss →
LFWD Lifeward Ltd.	E	31/100	—	96.0%	-35.0%	+0.71%	$16.7M	/lfwd-vs-mlss →
COCH Envoy Medical Inc. (Class A)	D-	35/100	—	-30.0%	-35.0%	+2.00%	$50.3M	/coch-vs-mlss →
MYO Myomo Inc.	E	33/100	—	65.7%	-35.0%	-4.61%	$51.5M	/myo-vs-mlss →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000855683

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Scientific Inc. (MLSS) reported GAAP revenue of $9.0M (+4.0% vs. FY2024 revenue of $8.6M ) , GAAP net income of $5.7M, operating cash flow of -$2.9M, and free cash flow of -$2.9M (-0.1% YoY). On the balance sheet, MLSS closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.0M	$5.7M	-$2.9M	-$2.9M	$7.8M	—
FY2024 (FY)	2024-12-31	$8.6M	$4.7M	-$2.9M	-$2.9M	$9.8M	—
FY2023 (FY)	2023-12-31	$0	$6.9M	-$5.3M	-$5.3M	—	—

3. MLSS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MLSS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MLSS compare to HSCS and LFWD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MLSS?

Where is MLSS trading relative to its 50-day, 200-day, and 52-week technical levels?

MLSS last traded at $0.30 (-3.30% on volume of 41,985 shares), positioning the stock -23.08% below its 50-day simple moving average ($0.39) and -14.29% below its 200-day simple moving average ($0.35). Across its 52-week range of $0.22 to $0.58, MLSS sits at the 22.2% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.34).

MLSS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does MLSS pay a dividend and is it safe?

Milestone Scientific Inc. (MLSS) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: MLSS RQD Cockpit MLSS 12M Forecast MLSS Earnings & Move MLSS Dividends & DRIP MLSS Insiders & 13F MLSS Whale Options MLSS Profit Sankey MLSS News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MLSS — Milestone Scientific Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:48:59Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MLSS scores 40 out of 100 with a letter grade of D- and a verdict of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 4 / 20. The pillar reflects ROIC of -35% and an FCF yield of -10.27%. For a prospective investor, this is the weakest part of the picture: the business is not currently generating returns on capital or positive free cash flow relative to its equity value.
Whale 13F Flow: 12 / 20. The pillar describes institutional accumulation and options positioning. This is a middling reading, suggesting some institutional participation without a strong conviction signal.
Insider Conviction: 7 / 20. Based on the SEC Form 4 and Congressional PTR cluster flow referenced in the rating, insider activity provides weak support for the thesis.
Macro Regime Fit: 4 / 20. With beta of 1.0 and the sector sensitivity noted in the rating, the rating indicates limited defensive or regime-specific advantage.
Forensic Balance Sheet: 13 / 20. The rating cites an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity of 0.5. This is the strongest pillar but still reflects a balance sheet that is not robust on the Piotroski scale.

Implications for a prospective investor: the upside case rests mainly on a turnaround in cash generation and a re-rating from very low multiples (P/E TTM of 5 and Forward P/E of 4.7 per market data), since the reported earnings do not appear to be supported by operating cash flow. The valuation tradeoff is that a low headline P/E can coexist with negative operating income and negative free cash flow, so low multiples here may reflect risk rather than mispricing. Liquidity and dilution risk should be weighed alongside any valuation argument. This is educational analysis, not personalized advice.

Business

Milestone Scientific Inc. is a NYSE-listed issuer classified in the Health Care sector and Industrial Specialties industry, per the profile. The source data does not describe its products, customers, or revenue model. Per the SEC financials, the company reported revenue of $9.0M for FY 2025 and $8.6M for FY 2024. Per the market data, gross margin is 71.4%. Source data does not detail how the company monetizes its offerings beyond these figures.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$9.0M	$-5.7M	$5.7M	N/A	$-2.9M	$1.1M	N/A
FY 2024	$8.6M	$-6.8M	$4.7M	N/A	$-2.9M	$3.3M	N/A
FY 2023	$0.0M	$-7.1M	$6.9M	N/A	$-5.3M	N/A	N/A

Per the market data, operating margin is -60% and net margin is 63.8%, a divergence that the source data does not explain. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. Cash declined from $3.3M to $1.1M across the reported FY 2024 to FY 2025 periods, and free cash flow was negative in each reported year.

Recent Catalysts & News Wire Analysis

Commercial growth update (GREEN, CATALYST): A WBOC TV-reported headline references a major commercial growth update tied to CompuFlo® expanding across 30 million+ annual global epidural procedures. This is the only item flagged as a catalyst in the source data.
Stock Titan headline (YELLOW): References potential single-use sales of about $33 million a year if the company reaches 2% of estimated U.S. epidural procedures. This is a conditional projection, not a reported result.
Market wire items (YELLOW): Moomoo, Yahoo Finance UK, TradingView, and Benzinga items are general market-action pieces with no specific fundamental content in the summaries.
Butterfly Supply-Chain Graph: Sector Health Care, industry Industrial Specialties, supply chain listed as NONE, with no butterfly links and no proprietary signals.

Risk watch: the source data contains no quantified commercial results supporting the growth update, and the $33 million figure is explicitly a potential rather than an actual.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no upstream or downstream links and no sector correlation links provided. Not available in source data for upstream supplier dependencies, downstream customer concentration, or 2nd-order bottlenecks.

Open Questions

What are the company's products, customer base, and revenue mix, given the source data offers only sector labels and aggregate revenue?
Why does the reported net income of $5.7M for FY 2025 coexist with an operating loss of $-5.7M and negative free cash flow?
What is the debt balance and maturity profile, since the debt field is N/A for all reported periods despite a Debt/Equity of 0.5?
Has the CompuFlo® commercial growth described in the news produced measurable revenue or order data yet?
What is the share count and dilution history, which is needed to interpret the $28.6M market cap and EPS against the $0.32 price?

MLSS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Milestone Scientific Inc. (MLSS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MLSS Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 14h ago

Milestone Scientific(MLSS) Stock Options Chain | Quotes & News

Moomoo report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 17h ago

Milestone Scientific, Inc. (MLSS) Seasonal returns chart

Yahoo Finance UK report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 20h ago

Milestone Scientific, Inc. Estimates – AMEX:MLSS

TradingView report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

Reaching 2% of estimated U.S. epidural procedures could mean about $33 million a year in potential single-use sales.

Stock Titan report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST WBOC TV • 1d ago

Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures

WBOC TV report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Monday's After-Market Session - Flyte Aviation (AMEX:VJET), Option Care H

Benzinga report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Retractable Technologies, Inc. (RVP) Seasonal returns chart

Yahoo Finance UK report covering Milestone Scientific Inc. (MLSS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MLSS Bull vs. Bear Conversation Board — What's Your Call at $0.30?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MLSS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.28 (-12.5%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MLSS (D- • RQD 40/100) a Buy at $0.32?

Welcome to the MLSS (Milestone Scientific Inc.) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Industrial Specialties. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.27 (-15.6%)

Spot @ $0.32

Pump the brakes on MLSS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MLSS, but look at what you are paying: 5.0x trailing P/E with 71.4% gross margins. Unless Milestone Scientific Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.40 (+25.0%)

Spot @ $0.32

MLSS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MLSS, the market is fixating on short-term headline noise in Industrial Specialties and ignoring the balance sheet and cash flow trajectory. At $0.32 (52-wk range $0.22 - $0.58), any beat on forward guidance forces shorts and underweight funds to chase.